TrialAnnals of oncology : official journal of the European Society for Medical Oncology2026

Alectinib versus crizotinib in previously untreated ALK-positive advanced non-small cell lung cancer: final overall survival analysis of the phase III ALEX study.

S Peters et al.PubMed ↗Publisher ↗

No numbers read from the abstract.